Immuneering-color-logo-CMYK_Resized.jpg
Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
October 15, 2024 08:00 ET | Immuneering Corporation
Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
Transparency Market Research
Molecular Oncology Market Size is projected to Reach USD 7.4 billion, Garnering an 11.0% by 2034: Transparency Market Research Inc.
October 11, 2024 08:41 ET | Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research Inc. -, Oct. 11, 2024 (GLOBE NEWSWIRE) -- The global molecular oncology market (분자종양학 시장) was projected to attain US$ 2.3 billion in...
Logo.png
Panavance Therapeutics Provides Update on Phase 1 Clinical Trial of Misetionamide in Pancreatic Cancer at 2024 Visceral Medicine Congress
October 09, 2024 07:07 ET | Panavance Therapeutics Inc.
Misetionamide-gemcitabine combination demonstrates very good safety profile and potential therapeutic benefit in the challenging treatment of pancreatic adenocarcinoma Interim results show ~40% of...
Dr. Daniel Von Hoff
Distinguished Oncologist, Professor Daniel Von Hoff joins the Scientific/Clinical Advisory Board of EnGeneIC Cancer Therapeutics
October 01, 2024 08:00 ET | EnGeneIC
EnGeneIC appoints Dr. Daniel Van Hoff to its Scientific Advisory Board to advise on clinical oncology programs, including upcoming PDAC trial.
22157.jpg
Oncology Collaboration and Licensing Agreements Analysis Report 2024: SEC-Linked Oncology Contract Documents Reveal In-Depth Deal Structures and Payment Clauses
September 30, 2024 05:03 ET | Research and Markets
Dublin, Sept. 30, 2024 (GLOBE NEWSWIRE) -- The "Oncology Collaboration and Licensing Deals 2019-2024" report has been added to ResearchAndMarkets.com's offeringThe report provides access to deal...
logo_urteste.png
Urteste Expands Development of Innovative Diagnostic Projects
September 26, 2024 10:29 ET | Urteste S.A.
               Urteste Expands Development of Innovative Diagnostic Projects Gdańsk, Poland – 26 SEPTEMBER 2024, 16:00 CET - Urteste S.A. (Warsaw Stock Exchange: URT),  a biotechnology company...
AIMLogo.jpg
AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
September 19, 2024 08:00 ET | AIM ImmunoTech Inc.
Preliminary finding of stable disease in two out of three patients at 6 months in the first subject cohort Combination of Ampligen and Imfinzi continues to be generally well-tolerated with no...
Immuneering-color-logo-CMYK_Resized.jpg
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients
September 12, 2024 16:05 ET | Immuneering Corporation
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line
Global Cancer Cachexia Market
Cancer Cachexia Market Forecasted to Reach $3.14 Billion by 2028 with a CAGR of 6.2% - Long-term Forecast to 2033
August 23, 2024 11:51 ET | Research and Markets
Dublin, Aug. 23, 2024 (GLOBE NEWSWIRE) -- The "Global Cancer Cachexia Market Report 2024" report has been added to ResearchAndMarkets.com's offering. Global cancer cachexia market is forecast to...
AIMLogo.jpg
AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
August 20, 2024 08:30 ET | AIM ImmunoTech Inc.
Data demonstrate compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through Ampligen Additional commentary published discussing the potential of Ampligen and...